Introduction
Injection of plasmid DNA into a tissue results in cellular uptake and expression of the encoded gene. 1, 2 Potential human clinical uses of such a plasmid DNA-based protein delivery method include immune response induction and modulation, therapeutic protein delivery and amelioration of genetic defects. For example, plasmid DNA may encode an antigen that induces an immune response against infectious pathogens or tumor cells. [3] [4] [5] [6] [7] The DNA may encode an immunomodulatory protein that diminishes an immune response against self antigens or modifies the immune response to allergens or transplanted tissues. [8] [9] [10] [11] [12] [13] [14] For therapeutic protein delivery, the plasmid DNA may encode, for example, an angiogenic protein, hormone, growth factor or enzyme. [15] [16] [17] [18] [19] [20] For amelioration of genetic defects, the plasmid DNA may encode normal copies of defective proteins such as dystrophin or the cystic fibrosis transmembrane conductance regulator. 21, 22 The therapeutic use of plasmid DNA-based protein delivery may benefit from an increased amount of gene expression from the injected DNA. Higher levels of expression in muscle can be obtained by using more potent DNA vectors, by delivering more copies of DNA into each cell nucleus or by delivering DNA to a greater number of cell nuclei in each multinucleate myofiber cell. tocrits by two-fold compared with DNA injected in saline. When the DNA encoded influenza nucleoprotein, sodium phosphate increased anti-nucleoprotein antibody titers by two-fold. The expression of luciferase from plasmid DNA instilled into lung was increased five-fold compared with that in vehicle without sodium phosphate. Incubation of plasmid DNA with muscle extract or serum showed that sodium phosphate protected the DNA from degradation. Thus, a change from sodium chloride to sodium phosphate vehicle can enhance the expression of plasmid DNA in a tissue, possibly by inhibiting DNA degradation. Gene Therapy (2000) 7, 1171-1182.
We have previously reported that luciferase reporter gene expression can be enhanced over 1600-fold (180 pg to 300 ng luciferase per muscle) 23 compared with levels first reported in 1990. 1 This was accomplished by systematically optimizing the regulatory, termination and backbone elements of the plasmid DNAs and testing them for expression using a standard in vivo muscle injection assay whereby 50 g of plasmid DNA in 50 l of saline is injected into mouse quadriceps and enzyme activity is extracted and measured 7 days later. 23, 24 Since the Hartikka et al 23 1996 publication, we have quantified the expression of an additional 100 plasmids each with specific modifications in promoter, enhancer, intronic, polyadenylation and backbone sequences 25 (and unpublished observations). None of these modifications resulted in even a two-fold enhancement of luciferase expression when compared with our optimized CMV-driven plasmids named VR1223 and VR1255. 23 Here, we have compared the effects of selected plasmid DNA vehicles on reporter gene expression in muscle.
Most investigators use normal saline vehicles for plasmid DNA injections because saline is isotonic, stable, nontoxic and has been used extensively for human intramuscular injection of other drugs. Here, we have investigated the effects of various plasmid DNA vehicle solutions on the subsequent expression of the encoded genes. We report that a 150 mm sodium phosphate vehicle, in the absence of saline, increases transgene expression when delivered with the plasmid DNA compared with a saline or PBS vehicle. This expression
Results
Requirements for sodium, chloride and phosphate ions The plasmids used in these studies are depicted in Figure  1 . Mouse quadriceps muscles were injected with 50 g of VR1223 luciferase DNA in 50 l of saline with or without sodium phosphate buffer and the muscles were extracted and assayed for luciferase activity 7 days later. The results are shown in Table 1 . With distilled water vehicle, luciferase expression was 30 times lower than with saline (4 versus 119 ng lux per muscle). Phosphate-buffered saline or PBS (ie saline plus 10 mm sodium phosphate) elicited a marginal, but statistically higher 1.6-fold expression level than saline (186 versus 119 ng luciferase per muscle, P = 0.02). Hypertonic solutions containing saline plus 100 mm sodium phosphate reduced expression to the level obtained using saline alone (117 versus 119 ng lux per muscle). Hypotonic 100 mm NaCl solution yielded the same expression as isotonic saline (112 versus 119 ng lux per muscle), but restoration of tonicity by the addition of 50 mm sodium phosphate to the 100 mm NaCl increased expression by 1.8-fold (112 versus 203 ng lux per muscle, P = 0.03). Thus, sodium phosphate seemed to increase luciferase expression and this effect was examined in more detail.
Sodium phosphate concentration studies
Luciferase expression from VR1223 DNA was examined in quadriceps muscle using vehicles containing different concentrations of sodium phosphate in the absence of NaCl. The averaged data from five separate experiments are shown in Figure 2 . The optimum sodium phosphate concentration was 150 mm which increased luciferase expression by 4.3-fold (386 versus 89 ng lux per muscle, P Ͻ 0.001) compared with saline (shown as a dashed line in Figure 2 ). This fold-enhancement range was the same for a less potent luciferase DNA vector that expressed 10-fold lower luciferase than VR1223 (data not shown). Vehicles containing sodium phosphate concentrations below 80 mm or above 200 mm resulted in plasmid DNA expression equal to or lower than saline vehicle.
To examine the effect of pH using the same vehicle, 23, 49, 57 150 mm sodium phosphate was prepared at pHs of 6.5, 7.5 or 8.0 and tested with VR1223 DNA for day 7 expression in quadriceps muscle. The results indicated that the optimum pH was 6.5 to 7.5, but pH 8.0 was suboptimal (data not shown). Based on the above data, 150 mm sodium phosphate was used at a pH of 7.0 for all subsequent studies.
The sodium, chloride and phosphate ions were replaced with various others and the resulting vehicles were compared with saline for their abilities to stimulate luciferase expression in muscle. The data for the 150 mm salts are shown in Table 2. Table 2A shows the effect on luciferase DNA expression when Na + in saline is replaced with other cations. Two salts, FeCl 2 and ZnCl 2 , were only tested in two or three mice, respectively, because these salts appeared to cause pain. All the divalent cations decreased expression while the monovalent K + elicited the same expression as the monovalent Na Table 2A -C, the stimulatory effects of various 150 mm vehicles can be ranked in order of decreasing stimulation as: sodium phosphate = potassium phosphate = sodium acetate Ͼ sodium pyruvate = sodium bicarbonate = sodium sulfate Ͼ saline = potassium chloride = sodium citrate. The rest of the vehicles tested inhibited expression compared with saline.
Effects of osmolarity and pH
The osmolarity and pH of each vehicle shown in Table 2 was measured and plotted versus the 7 day luciferase expression level obtained with that vehicle (data not shown). The osmolarity graph revealed that vehicle osmolarities between 271 and 349 mmol/kg generally yielded the highest expression levels but the exceptions included 50 and 100 mm sodium phosphate at 83 and 270 mmol/kg (respective expression levels were 2.1-and 2.3-fold those of saline at 310 mmol/kg) and sodium citrate at 394 mmol/kg (expression level was the same as with saline). The 150 mm sodium phosphate vehicle yielded an expression level that was four-fold higher than that of saline, yet both vehicles had the same osmolarity (310 versus 308 mmol/kg, respectively). The pH graph revealed that the highest expression levels were generally obtained at pH 6.0 to 7.5. However, some exceptions were sodium sulfate, pH 5.5, and sodium bicarbonate, pH 9.0, which yielded expression levels that were 2.6-and 2.8-fold, respectively, over saline at pH 5.5. Magnesium phosphate vehicle had a pH of 7.0 but yielded expression lower than saline. Thus, the enhanced expression of luciferase plasmid DNA in muscle can occur with vehicles having different osmolarities or pHs.
Reproducibility of sodium phosphate enhanced luciferase DNA expression Nine repeat experiments were carried out to test the reliability of 150 mm sodium phosphate vehicle to enhance plasmid DNA expression in mouse skeletal muscle. In each experiment, 10 quadriceps muscles were injected with 50 g VR1223 luciferase DNA in 50 l of either saline or 150 mm sodium phosphate. Muscles were collected and assayed for luciferase 7 days later. The averaged results for each experiment are shown in Figure 3 . Compared with saline, sodium phosphate enhanced luciferase expression in all these experiments and this enhancement ranged from 2.5-fold (156 versus 384 ng lux per muscle for experiment 9) to 7.3-fold (49 versus 362 ng lux per muscle in experiment 1). The average enhancement by sodium phosphate in the combined experiments was about four-fold.
Sodium phosphate effects on the expression of ␤-galactosidase and interferon It was determined whether sodium phosphate vehicle could enhance the intramuscular expression of plasmid DNAs encoding reporter proteins other than luciferase. Plasmids encoding ␤-galactosidase (VR1418) and secreted human interferon-omega (IFN-; VR4151) in saline or 150 mm sodium phosphate were injected into mouse quadriceps. Muscle extracts were assayed for ␤-galactosidase and the serum was assayed for circulating levels of IFN-. The 7 day post-DNA injection data, including luciferase plasmid DNA for comparison, are shown in Figure 4 . The 150 mm sodium phosphate vehicle enhanced the apparent expression of all three reporter genes over saline. The sodium phosphate vehicle significantly enhanced the expression of plasmid DNA encoding luciferase by 4.0-fold (481 versus 119 ng per muscle; P Ͻ 0.001), ␤-galactosidase by 3.3-fold (9.8 versus 3.0 ng per muscle; P = 0.001) and serum IFN-by 2.5-fold (0.35 versus 0.14 ng per ml serum; P = 0.020). A PBS vehicle, run in parallel, elicited statistically equivalent expression as saline using either the ␤-galactosidase or IFN plasmids (data not shown). A sodium phosphate dose-response performed with ␤-galactosidase DNA showed that 150 mm sodium phosphate was the optimal concentration just as it was for luciferase DNA (data not shown). This similar dose-response effect occurred despite the fact that the ␤-galactosidase DNA, unlike the luciferase or IFN-DNA, is driven by an RSV promoter rather than CMV, and was injected at 10 g DNA per muscle rather than 50 g.
Sodium phosphate vehicle effects on the time-course of secreted protein expression Three plasmid DNAs encoding a secreted form of human placental alkaline phosphatase (SEAP; VR3301), rat preproinsulin (VR3502) or mouse erythropoietin (EPO; VR2901) were injected into mouse skeletal muscle in saline or sodium phosphate vehicles and the mice were monitored over time for blood levels of SEAP or proinsulin or for hematocrits. The results are shown in Figure 5 . The SEAP and proinsulin DNAs were injected into the tibialis anterior muscles. SEAP DNA was injected into nude mice to minimize an immune response to the strongly immunogenic transgene product. The kinetics of blood SEAP levels from mice injected with DNA in both vehicles were similar. SEAP protein rose to a peak level at 7 days, then declined to 40-45% of the maximum expression level where it remained for the following 9 weeks. Over this 9 week period, sodium phosphate vehicle significantly enhanced SEAP expression at every time-point by 1.4-to 1.8-fold compared with saline (n = 15 per time-point; P = 0.002-0.037). A parallel experiment using PBS showed expression to be statistically equivalent to that obtained with saline (data not shown). Thus, the use of sodium phosphate vehicle elicited a higher level of sustained expression from plasmid DNA than the use of saline.
With rat preproinsulin DNA injected into immunocompetent mice, sodium phosphate vehicle enhanced expression at each time-point over a 14 day period by 1.9-to 3.8-fold compared with saline vehicle (n = 10 per time-point; P Ͻ 0.01). With mouse EPO DNA injected into the muscles of immunocompetent mice, hematocrits rose steadily over 4 weeks. Control mice injected with 20 g of DNA encoding canine clotting factor IX exhibited an average hematocrit of 46. The use of sodium phosphate vehicle resulted in higher hematocrits at each timepoint compared with the use of saline vehicle. This enhancement ranged from 1.4-to 2.1-fold (n = 10; P = 0.02-0.001).
Effect of sodium phosphate vehicle on plasmid DNA immunization Sodium phosphate vehicle was tested to determine if it would enhance immune responses against plasmid DNA encoded antigen. Mice were vaccinated i.m. with VR4700 influenza NP DNA in saline or 150 mm sodium phosphate vehicles and the mice were monitored for the pres- ence of circulating anti-NP antibodies and for an NPspecific cytotoxic T lymphocyte response (CTL). The antibody data at 6 weeks and CTL data at 9 weeks after vaccination are shown in Figure 6 . Figure 6a shows that in three replicate experiments (labeled 1-3, n = 10 mice per experiment), sodium phosphate enhanced serum anti-NP antibody titers compared with saline vehicle. The enhancement by sodium phosphate was significant for each individual experiment (P Ͻ 0.04) and when the three experiments were averaged (P Ͻ 0.001). NP DNA injected in PBS was run in parallel and the antibody titers were not statistically different from those using saline vehicle (data not shown). Figure 6b shows that anti-NPspecific CTL activity was statistically similar (P Ͼ 0.05) in the saline and 150 mm sodium phosphate groups. A repeat set of CTL experiments showed the same result (data not shown).
Histology of muscle transduction
We used the LacZ plasmid system to determine if muscle transduction using a sodium phosphate vehicle remains restricted to myofiber cells as it does when using a saline vehicle. Twenty-six BALB/c quadriceps muscles each were injected with 50 g VR1412 LacZ DNA in 50 l of either saline or 150 mm sodium phosphate and the muscles were collected 7 days later and stained for ␤-galactosidase. Representative photographs of transduced muscles are shown in Figure 7 . Fixed and stained whole muscles or muscle sections are shown in Figure 7A , C, E (saline) and 7B, D, F (sodium phosphate). On average, ␤-galactosidase staining appeared greater in the phosphate injected muscles than for saline injected muscles. Inspection of muscle sections from both groups revealed that only myofiber cells exhibited ␤-galactosidase staining and there was no ␤-galactosidase-positive staining of tendon, vasculature, connective tissue or satellite cells. Cell counts of sections taken from the midline of muscles revealed that the sodium phosphate group contained more ␤-galactosidase-positive myofiber cells than did the saline group (108 ± 21 versus 186 ± 43 myofiber cells per muscle section; P = 0.02; n = 10). Sodium phosphate affects plasmid DNA expression in a non-muscle tissue using lipofection Skeletal and cardiac muscle are unique tissues in their ability to express injected naked plasmid DNA encoded gene products at high levels. However, non-muscle tissues can express lower levels of such gene products if the DNA is delivered with a carrier such as cationic liposomes. 2, 24, 26 To determine if sodium phosphate vehicle could enhance the expression of plasmid DNA in a non-muscle tissue using cationic liposomes, mouse lungs were instilled with VR1223 luciferase plasmid DNA-GAP-DLRIE complexes in water or selected concentrations of sodium phosphate. The use of DNA-lipid complexes in water vehicle and the 3 day collection-time were previously found to yield peak lung transfection.
2,26
The results are shown in Figure 8 . The level of luciferase expression in lung using water (0.94 ng lux per lung) is comparable with published reports 2 and is similar to the level of expression obtained in muscle tissue using the same vector in water without lipid (cf. Figure 8 ). Thus, sodium phosphate can enhance luciferase expression in lung, but does so at a much lower concentration than that which is effective in muscle. 
Gene Therapy
Sodium phosphate inhibits muscle DNase activity One mechanism by which sodium phosphate could enhance plasmid DNA expression in muscle is inhibition of DNA degradation. To assess this possibility, aliquots of plasmid DNA in various vehicles were spiked with mouse muscle extract or serum. The reactions were incubated for 2 h at 37°C in the presence of water, saline or 150 mm sodium phosphate. After incubation, DNA degradation was analyzed by agarose gel electrophoresis. The results are shown in Figure 9 . Incubation of plasmid DNA in water with 10% v/v muscle extracts or serum resulted in the complete degradation of the DNA (compare the left two lanes in Figure 9) . A significant amount of the DNA was protected in the presence of both saline and sodium phosphate. However, sodium phosphate vehicle protected the DNA considerably better than did saline (compare the right two lanes in Figure 9 ; note the presence of remaining closed circular form in muscle extract and remaining nicked form in serum for sodium phosphate vehicle). Similar results were obtained in replicate experiments (data not shown). The inhibition of DNA degradation correlated with the increase in gene expression observed for DNA injected into muscle (compare ng luciferase expression values taken from Tables 1 and 2 and shown at the bottom of each lane in Figure 9 with the presence of nicked and closed circular DNA).
Discussion
Evidence is presented that plasmid DNA injected in 150 mm sodium phosphate reaches higher levels of expression when injected into muscle compared with DNA formulated in saline. When the plasmid DNAs encoded secreted proteins, sodium phosphate vehicle increased the circulating levels of each gene product compared with saline vehicle. When the plasmid DNAs encoded proteins with biological activity, sodium phosphate tended to increase the biological responses to the protein.
Histological analysis of muscles injected with LacZ DNA in either saline or sodium phosphate vehicle showed the transduction of only myofiber cells. Counting of ␤-gal stained fibers showed a greater number of ␤-gal stained myofiber cells in the sodium phosphate group than in the saline group. Sodium phosphate appears to increase the transduction of muscle cells when used to deliver plasmid DNA.
The mechanism by which sodium phosphate enhances plasmid DNA expression in muscle is not known. Sodium phosphate could mediate gene expression through actions on myofiber cells and/or on the plasmid DNA itself. Sodium phosphate anion is a metabolite of creatine phosphokinase and ATPase, two enzymes that generate phosphodiester bond energy for skeletal muscle contraction. In resting myofiber cells, intracellular phosphate ion concentrations are 1-6 mm and can accumulate in muscle contraction to levels approaching 30 mm, which inhibits force production and slows muscle relaxation in skeletal muscle fatigue. [27] [28] [29] [30] [31] Phosphate ion applied intracellularly or extracellularly to myofiber cells enters the sarcoplasmic reticulum and precipitates calcium, which in turn decreases muscle contraction. 32, 33 Thus, sodium phosphate injections into muscle could somehow aid the entry of plasmid DNA into muscle cells. It has been reported that calcium is required for cell membrane resealing by a process involving recruitment of intracellular membrane vesicles which bind to, fuse with and patch damaged plasmalemma. 34 We have previously shown that intramuscular injection of plasmid DNA results in an initially high expression at the myotendinous junction, 35 a site others have shown to experience repeated contraction-induced interruptions and exocytotic repair of the plasmalemma. [36] [37] [38] Sodium phosphate, by precipitating calcium ions required for exocytosis, could increase transduction by delaying the repair of broken cell membranes, allowing more plasmid DNA to enter the myofiber cell.
Extensive studies have shown that plasmid DNA becomes tightly interwound and compacted in the presence of various salts at physiological concentrations. [39] [40] [41] [42] [43] Sodium phosphate might compact the DNA better or differently than does sodium chloride and thus render the DNA more resistant to DNase activity. Such a compaction of DNA may even reduce the size or surface charge of plasmid enough to facilitate its entry into myofiber cells. Alternatively, sodium phosphate may prolong the availability of intact DNA by inhibiting its degradation. Reversible inhibition of non-mammalian DNases by phosphate anion has been described. [44] [45] [46] A structural analysis of DNase I, the major mammalian serum endonuclease, revealed numerous contacts between the enzyme and phosphate groups present in the DNA substrate backbone. 47 High concentrations of phosphate anion may act as a competitive inhibitor of DNase I. Consistent with this hypothesis, we show in the present study that plasmid DNA diluted in 150 mm sodium phosphate is resistant to degradation by nucleases present in muscle extract or serum. We have also observed that plasmid DNA diluted in 150 mm sodium phosphate was completely resistant to degradation by purified bovine pancreatic DNase I (unpublished observations). Well-established DNase inhibitors such as sodium citrate, which inhibits DNase by chelating divalent cations required for its activity, aurintricarboxylic acid (ATC), which inhibits DNase by tightly intercalating into the DNA helix, and purified soluble actin, a potent non-competitive inhibitor of DNase activity 48 all failed to increase intramuscular luciferase activity when co-injected with the DNA 15, 49 (and unpublished observations). However, sodium citrate, ATC and actin may act through fundamentally different mechanisms than sodium phosphate, or could diminish expression via intramuscular toxicity or transcriptional inactivation of the DNA. Thus, sodium phosphate still may, at least in part, enhance expression of injected plasmid DNA by inhibiting DNA degradation in injected muscles.
Another potential mechanism for the sodium phosphate-mediated enhancement of plasmid DNA expression is that sodium phosphate could increase the distribution of the DNA in the injected muscle. This could occur by an action on the extracellular spaces or cell surfaces. For example, sodium phosphate could monopolize phosphate-binding sites that might otherwise bind the phosphate backbone of the DNA and retard its diffusion and entry into cells.
It is interesting that sodium phosphate vehicle enhanced the expression of plasmid DNA when administered as a liposome complex to mouse lung. Previous work has shown that the major cell type transduced with plasmid DNA-cationic lipid complexes in the lung is alveolar cells. 2 Intranasal instillation of plasmid DNA should result in less direct lung tissue damage and bleeding in the lung than needle injections into muscle, and thus one might expect less release of DNases into fluids containing the plasmid DNA. Cationic lipid carrier is required to deliver the plasmid DNA into non-muscle cells such as lung 2 and cationic liposomes protect DNA from degradation by DNases. 50 Sodium phosphate vehicle enhanced this lipid-mediated transduction of lung. Sodium or potassium phosphate have been reported to enhance Lipofectin-mediated transfection of human osteosarcoma cells in vitro, 51 and RPMI cell culture medium buffered with NaHCO 3 /Na 2 HPO 4 was reported to be the best vehicle for plasmid DNA-liposome-based transfection in vitro. 52 In any case, sodium phosphate vehicle may find wider in vivo utility in the delivery of plasmid DNA to non-muscle tissues.
In conclusion, a change in the salt composition of an injection vehicle (sodium chloride to sodium phosphate) reproducibly enhanced the subsequent expression from various plasmids when injected into murine muscle. Such an observation is surprising and underscores our lack of understanding of the mechanism of cellular uptake and expression of injected plasmid DNA. Nevertheless, this 'phosphate effect' may lead to further vehicle improvements and to a better understanding of the physiological and biochemical processes governing plasmid DNAbased protein delivery. Sodium phosphate in the absence of saline has been used in humans at 5 mm to 190 mm as a vehicle for drugs administered via the intramuscular or intravenous routes. 53 We are currently determining if sodium phosphate can enhance plasmid DNA-based, therapeutic protein delivery in larger animals and humans.
Materials and methods

Reagents
All salts used to test vehicle effects on muscle transfection were purchased from Sigma Chemical Corporation (St Louis, MO, USA). Purified plasmid DNA was ethanol precipitated and resuspended in water. Salt solutions were prepared as 300 mm stock solutions and dilutions were made using sterile USP water (Baxter, Deerfield, IL, USA). Figure 1 depicts the major structural and regulatory elements contained in each plasmid. Details regarding construction of these vectors have been previously described. The gene for Photinus pyralis (firefly) luciferase was subcloned from the pSP-Luc+ plasmid (Promega, Madison, WI, USA) into the VR1012 plasmid 49 to make VR1223 or VR1255. 23 The RSV promoter-regulated VR1418 LacZ vector was made by subcloning the LacZ gene from the VR1412 vector 27 into VR1043, itself derived by replacing the CMV control elements of VR1012 with RSV control elements. The mouse EPO gene was obtained by PCR as described 16 and subcloned into the VR1012 vector. The secreted form of the human placental alkaline phosphatase (SEAP) gene was subcloned from pSEAP2-Basic (Clontech, Palo Alto, CA, USA) into the VR1012 backbone vector to make VR3301. A mutagenized rat preproinsulin I coding sequence was obtained from reverse transcription of rat pancreatic preproinsulin poly(A) mRNA followed by site-directed mutagenesis as described. 54 The human IFN-coding sequence was obtained by amplifying the coding sequence from human genomic DNA prepared from DNA of fresh human blood. The IFN-gene was subcloned into the VR1055 vector as described. 5 The luciferase gene in VR1255 was replaced with the influenza A/PR/8/34 nucleoprotein gene as described 4 to yield VR4700.
Plasmid DNA purification Plasmid DNA was transformed into Escherichia coli DH10B competent cells and highly purified covalently closed circular plasmid DNA was isolated by a modified lysis procedure 55 followed by standard double CsCl-ethidium bromide gradient ultracentrifugation and dialysis. 56 SEAP and preproinsulin encoding plasmid DNAs were purified using Giga columns from Qiagen (Valencia, CA, USA) according to the kit instructions. All plasmid preparations were free of detectable chromosomal DNA, RNA and protein impurities based on gel analysis and the bicinchoninic protein assay (Pierce, Rockford, IL, USA). Endotoxin levels were measured using Limulus Amebocyte Lysate assay (LAL; Associates of Cape Cod, MA, Gene Therapy USA) and were less than 0.01 endotoxin units/g of plasmid DNA. The spectrophotometric A 260 /A 280 ratios of the DNA solutions were typically above 1.8. Plasmids were ethanol precipitated and resuspended in water at 4°C until completely dissolved. DNA was stored at −20°C until use. DNA was diluted by mixing it with 300 mm salt solutions and by adding the appropriate amount of USP water to obtain 1 mg/ml plasmid DNA in the desired injection vehicle.
Injections of plasmid DNA The quadriceps muscles (or tibialis anterior muscles for SEAP and preproinsulin plasmids) of restrained awake mice (female 6-to 12-week-old BALB/c or Nude, nu/nu, from Harlan Sprague Dawley, Indianapolis, IN, USA) were injected with 50 g of DNA or 2 × 100 g preproinsulin DNA in 50 l vehicle using a disposable insulin syringe and 28G 1/2 needle (Becton Dickinson, Franklin Lakes, NJ, USA; Cat. No. 329430) fitted with a plastic collar cut from a micropipette tip, all as previously described. 23 The tissues were extracted and assayed as described. 24 Nude mice were injected with VR3301 DNA bilaterally on 3 consecutive days for a total of 300 g DNA per mouse. Lungs were instilled with 132 g plasmid DNA complexed with GAP:DLRIE cationic liposomes in vehicle and extracted as described. Luciferase and alkaline phosphatase enzyme assays Luciferase activity was assayed using a Dynatech model ML2250 microplate luminometer (Chantilly, VA, USA) as previously described. 23 The luciferase content of the samples was calculated from relative light units using a standard curve of purified firefly luciferase (Analytical Luminescence Labs, San Diego, CA, USA; Cat. No. 2400), which was diluted in pooled extract from uninjected muscles or lungs to control for quenching. Luciferase values were expressed as ng luciferase per muscle or lung. The level of ␤-galactosidase expression in muscle extracts was quantified using a chemiluminescent assay according to the manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN, USA; Cat. No. 1758241). A standard curve, prepared in pooled extract from uninjected muscles or lungs, was included on each plate using the ␤-galactosidase enzyme standard included in the kit.
Sera from nude mice injected with VR3301 were collected at various times after injection. Five l of serum was mixed with 15 l ddH 2 O and placed into individual wells of a 96-well plate (Costar EIA/RIA A/2, Corning, NY, USA; Cat. No. 3690). A serial dilution of EIA grade calf intestinal alkaline phosphatase (CIP, Boehringer Mannheim 567 744) in PBS containing 0.05% BSA was used to produce a standard curve. Samples were assayed in duplicate. Plates were sealed, incubated at 65°C for 30 min and spun for 5 minutes at 4000 r.p.m. at room temperature. Each well received 100 l substrate solution containing 1 mg/ml para-nitrophenyl phosphate (PNPP; Boehringer Mannheim, 107 905) and 1 mm MgCl 2 in 1 m diethanolamine, pH 9.8. The samples were analyzed using a Molecular Devices Opti-Max plate reader (Sunnyvale, CA, USA). The plate reader was pre-warmed to 37°C and a standard kinetic program was used to assay the samples at a wavelength of 405 nm for 30 min.
Anti-NP antibody titer assays Sera were collected at different times before and after plasmid DNA injections. Ninety-six-well plates (Corning Incorporated, Corning, NY, USA; Cat. No. 3690) were coated with 250 ng/100 l PBS per well of NP purified from recombinant baculoviral extracts. The plates were stored overnight at 4°C and the wells washed twice with BBST (89 mm boric acid + 90 mm NaCl, pH 8.3 + 234 mm NaOH supplemented with 0.05% Tween 20 (v/v). The wells were then incubated for 90 min with BB (BBST in which the Tween was replaced with 1% bovine serum albumin, w/v) and washed twice with BBST again. Twofold serial dilutions of mouse serum in BB starting at 1:20 were made in successive wells and the solutions were incubated for 2 h at room temperature. Wells were then rinsed four times with BBST. Sera from mice hyperimmunized with VR4700 NP plasmid DNA were used as a positive control and pre-immune sera were used as negative controls.
To detect specific antibodies, alkaline phosphataseconjugated goat anti-mouse IgG-Fg (Jackson ImmunoResearch, West Grove, PA, USA) diluted 1:5000 in 5% nonfat milk were added at 100 g per well and the plates were incubated at room temperature for 2 h. After four washings in BBST, the substrate (1 mg/ml p-nitrophenyl phosphate, Calbiochem, San Diego, CA, USA; Cat. No. 4876 in 50 mm sodium bicarbonate buffer, pH 9.8 and 1 mm MgCl 2 ) was incubated for 90 min at room temperature and absorbance readings were performed at 405 nm. The titer of the sera was determined by using the reciprocal of the last dilution still giving an optical density value two times above background. Background was established using pre-immune serum diluted 1:20.
Serum concentrations of human IFN-were measured using a commercially available kit with a detection limit of 2 pg/ml (Alexis, San Diego, CA, USA). Rat serum proinsulin was measured by ELISA as previously described. 54 Hematocrit measurements Hematocrits were measured by centrifugation of blood obtained from the retro-orbital cavity of mice. Blood samples were collected in 75 l heparinized capillary tubes and analyzed using HemaSTAT II microhematocrit centrifuge (Separation Technology, Altamonte Springs, FL, USA).
Histology
For whole muscle staining, quadriceps were fixed for 3 h at room temperature in 2% paraformaldehyde in PBS, washed three times for 20 min each in PBS and incubated for 18 h at 37°C in a solution containing 2 mm MgCl 2 , 5 mm potassium ferricferrocyanide and 1 mg/ml 5-bromo-4-chloro-3-indoyl-␤-d-galactosidase (Gibco BRL, Gaithersburg, MD, USA) in PBS. After incubation, the muscles were washed three times for 10 min each in 3% dimethyl sulfoxide in PBS and stored in PBS at 4°C until analysis. To prepare stained tissue cross-sections, quadriceps were snap-frozen in liquid nitrogen-cooled isopentane, cut in half, embedded in OCT (VWR, McGraw Park, IL, USA) and 10 m sections cut using a Jung Frigocut Model 2800E cryostat (Leica, Foster City, CA, USA). Sections were collected on 1% gelatin-coated glass slides, brought to room temperature and stained for 2 h at 37°C in the same reagent as for whole mounts above except that the galactosidase reagent concentration was 200 g/ml. The sections were then counterstained with Harris hematoxylin in acetic acid, rinsed in tap water, dehydrated and mounted in Permount (Fisher, Fair Lawn, NJ, USA). The number of ␤-galactosidase-positive cells per muscle was determined by light microscopy in muscle cross-sections as described. 35 
CTL assays
To generate CTL effector cells from plasmid DNA immunized BALB/c mice, splenocytes were stimulated in culture for 5 days with NP 147-155 peptide (TYQRTRALV) pulsed, irradiated splenocytes from naive BALB/c mice. For the stimulation cultures, splenocytes from naive mice were ␥-irradiated with 3200 rad and pulsed with 10 m of the H-2K d -restricted NP 147-155 peptide for 40 min at 37°C. Then, 2.5 × 10 7 test splenocytes from DNA immunized mice were incubated at 37°C in 5.5% CO 2 with an equal number of irradiated, pulsed splenocytes from naive mice in 25 cm 2 flasks containing 25 ml RPMI 1640 media with l-glutamine and 25 mm Hepes supplemented with 10% fetal bovine serum, penicillin (100 U/ml), streptomycin (100 g/ml) and 5.5 × 10 −5 m ␤-mercaptoethanol). After 24 h of culture, recombinant murine IL-2 was added to a final concentration of 1 U/ml.
To measure specific lysis of NP 147-155 peptide pulsed target cells by CTL effector cells, P815 cells (American Type Culture Collection, Manassas, VA, USA) were labeled with Na 2
51
CrO 4 (NEN Life Scientific Products, Boston, MA, USA). Aliquots of 51 Cr-labeled cells were either pulsed with 10 m NP 147-155 or were used unpulsed. For the CTL assay, stimulated splenocytes were serially diluted in 96-well round bottom microtiter plates (ICN Biomedicals, Aurora, OH, USA). Target cells were added in a final volume of 100 l per well. After incubation for 5 h at 37°C in 5.5% CO 2 , 100 l of RPMI 1640 complete media was added to each well, the plates were centrifuged and 100 l per well was removed for analysis in a Cobra II gamma counter (Packard Instruments, Downers Grove, IL, USA). The percentage of specific lysis was calculated as % specific lysis = (a − b/c − b) 100 where a is the average c.p.m. released in the presence of effectors, b is the average spontaneous c.p.m. released from target cells incubated in media only and c is the maximum c.p.m. released from target cells in the presence of 1% Triton X-100.
DNase inhibition assay
Quadriceps muscles were harvested from naive mice as previously described. 23 Ten muscles were pooled and ground at 4°C without adding buffer using a Duall tissue grinder with ground glass pestle (Kontes Glass, Vineland, NJ, USA), centrifuged at 13 000 g for 20 min, and the supernatant was collected and stored at −20°C. Serum was collected from 10 naive mice by orbital sinus puncture, pooled and stored at 4°C. For the assay, VR1255 DNA was diluted to 0.25 g/ml in the respective vehicle, mixed with 0.1 volume of muscle extract or serum, and incubated at 37°C for 2 h. The samples were neutralized by adding an equal volume of 2% sodium dodecyl sulfate + 50 mm EDTA and 4 l of sample was analyzed by electrophoresis on 0.8% agarose Tris Acetate EDTA gels with ethidium bromide staining.
Statistical evaluations
Statistical comparisons from muscle expression data were performed using the non-parametric Mann-Whitney rank sum test (SigmaStat version 2.03; Jandel Scientific Software, San Rafael, CA, USA) or by the standard Student t test. Differences were considered statistically significant when the P value was less than 0.05.
